LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent

Several cationic antimicrobial peptides demonstrate promising anticancer effects. We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete regression of B16 melanomas and systemic protective imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Camilio, Ketil André, Rekdal, Øystein, Sveinbjörnsson, Baldur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108458/
https://www.ncbi.nlm.nih.gov/pubmed/25083333
http://dx.doi.org/10.4161/onci.29181
_version_ 1782327761458692096
author Camilio, Ketil André
Rekdal, Øystein
Sveinbjörnsson, Baldur
author_facet Camilio, Ketil André
Rekdal, Øystein
Sveinbjörnsson, Baldur
author_sort Camilio, Ketil André
collection PubMed
description Several cationic antimicrobial peptides demonstrate promising anticancer effects. We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete regression of B16 melanomas and systemic protective immune responses following intralesional administration of the peptide.
format Online
Article
Text
id pubmed-4108458
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41084582014-07-31 LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent Camilio, Ketil André Rekdal, Øystein Sveinbjörnsson, Baldur Oncoimmunology Author's View Several cationic antimicrobial peptides demonstrate promising anticancer effects. We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete regression of B16 melanomas and systemic protective immune responses following intralesional administration of the peptide. Landes Bioscience 2014-06-25 /pmc/articles/PMC4108458/ /pubmed/25083333 http://dx.doi.org/10.4161/onci.29181 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Camilio, Ketil André
Rekdal, Øystein
Sveinbjörnsson, Baldur
LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
title LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
title_full LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
title_fullStr LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
title_full_unstemmed LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
title_short LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
title_sort ltx-315 (oncopore™): a short synthetic anticancer peptide and novel immunotherapeutic agent
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108458/
https://www.ncbi.nlm.nih.gov/pubmed/25083333
http://dx.doi.org/10.4161/onci.29181
work_keys_str_mv AT camilioketilandre ltx315oncoporeashortsyntheticanticancerpeptideandnovelimmunotherapeuticagent
AT rekdaløystein ltx315oncoporeashortsyntheticanticancerpeptideandnovelimmunotherapeuticagent
AT sveinbjornssonbaldur ltx315oncoporeashortsyntheticanticancerpeptideandnovelimmunotherapeuticagent

Ejemplares similares